Jess brings a background in biologics process development to Kimer Med, where she is responsible for commissioning the pilot plant and establishing the upstream and downstream processes that will produce material for pre-clinical studies. Her remit extends to the robust, well-documented processes that can be transferred to GMP manufacture as the company's antiviral candidates advance toward the clinic.

She has spent her career in early-stage biotech. At Invenra she led both the analytics and purification functions of the protein sciences team, supporting biologics drug-discovery lead selection on one side and process development and CMC activities on the other. Earlier, at Aldevron and Catalent Pharma Solutions, she developed downstream purification processes, ran pilot-scale manufacturing, and authored the technology transfer documentation that carried those processes into GMP campaigns and IND filings.

Jess holds a PhD in Molecular Biophysics and Biochemistry from Yale University, where her research focused on the structure and function of Photosystem II, the protein complex at the heart of photosynthesis.